Oncology Abbreviations

• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z

A

AAA

Abdominal aortic aneurysm

ABD

Abdominal

AML

Acute myeloid leukemia

ANC

Absolute neutrophil count

ASCO

American Society of Clinical Oncology

ASEL

Agent Specific Adverse Event List

AST

Aspirate aminotransferase

ATE

Arterial thromboembolic event

AUC

Area under the concentration–time curve

AUC (ø-t)

Area under the concentration–time curve between time ø and t

^Top

B

BCS

Breast cancer–specific

bFGF

Basic fibroblast growth factor

b-IfL

Bolus IfL (irinotecan with bolus 5-fluorouracil/leucovorin) (Saltz regimen)

BUN

Blood urea nitrogen

^Top

C

C

Cycle

CAD

Coronary artery disease

CAEPR

Comprehensive Adverse Event and Potential Risks

CALGB

Cancer and Leukemia Group B

CBC

Complete blood count

CCS

Colorectal cancer–specific

CEA

Carcinoembryonic antigen

CHF

Congestive heart failure

CI

Confidence interval

CL

Clearance

Cmax

Maximum concentration

CNS

Central nervous system

CP

Carboplatin/paclitaxel chemotherapy

CPT-11

Irinotecan (Camptosar®)

CR

Complete response

CRC

Colorectal cancer

CRF

Case Study Report

CRO

Contract research organization

CSR

Clinical Study Report

CT

Computed tomography

CTEP

Cancer Therapy Evaluation Program

CTMB

Clinical Trials Monitoring Branch

CTMU

Clinical Trials Management Unit

CTSU

Cancer Trials Support Unit

CV

Coefficient of variation

^Top

D

DCO

Data coordinating organization

D/C’d

Discontinued

df

Degree of freedom

DHHS

Department of Health and Human Services

DM

Diabetes mellitus

DMC

Data Monitoring Committee

DST

Duration of study therapy

DVT

Deep venous thrombosis

^Top

E

ECOG

Eastern Cooperative Oncology Group

EGFR

Epidermal growth factor receptor

ELISA

Enzyme-linked immunosorbent assay

EORTC

European Organization for Research and Treatment of Cancer

EPP

Expanded Participation Project

ER

Estrogen receptor

EWB

Emotional well-being

^Top

F

FACT-B

Functional Assessment of Cancer Therapy-Breast

FACT-C

Functional Assessment of Cancer Therapy-Colorectal

FDA

Food and Drug Administration

FEV1

Forced expiratory volume in 1 second

FISH

Fluorescent in situ hybridization

FOCE

First-order conditional estimation

FOLFOX

Oxaliplatin, continuous infusion 5-fluorouracil, and leucovorin

FOLFOX4

Oxaliplatin/5-fluorouracil/leucovorin

FWB

Functional well-being

5-FU

5-fluorouracil

5-FU/LV

5-fluorouracil/leucovorin

^Top

G

GCP

Good clinical practice

GCS

Georgia Cancer Specialists

GCSF

Granulocyte colony-stimulating factor

GFR

Glomerular filtration rate

GI

Gastrointestinal

GOG

Gynecologic Oncology Group

^Top

H

HGC

Human chorionic gonadotropin

Hc+

Hematocrit

HER2

Human epidermal growth factor receptor 2

HR

Hazard ratio

HRP

Horseradish peroxidase

HTN

Hypertension

^Top

I

ICAM-1

Intercellular adhesion molecule-1

ICF

Informed consent form

ICTI

Interactive Clinical Technologies, Inc.

IEC

Independent ethics committee

IFL

Irinotecan/5-fluorouracil/leucovorin

IgG

Immunoglobulin G

IHC

Immunohistochemistry

IND

Investigational New Drug

INR

International normalized ratio

IRB

Institutional Review Board

IRF

Independent radiologic facility

ITT

Intention-to-treat

IV

Intravenous

IVRS

Interactive voice response system

^Top

K

KUB

Kidney, ureter, bladder

^Top

L

LFT

Liver functional test

LTR

Less than reportable

LV

Leucovorin

^Top

M

MAB

Monoclonal antibody

MBC

Metastatic breast cancer

MDS

Myelodysplastic syndrome

MID

Minimally important difference

MOF

Minimum objective function

MRI

Magnetic resonance imaging

^Top

N

NA

Not applicable

NCCTG

North Central Cancer Treatment Group

NCI

National Cancer Institute

NCI CTC

National Cancer Institute Common Toxicity Criteria non-protocol therapy

NCIC

National Cancer Institute of Canada

NCIC CTG

National Cancer Institute of Canada Clinical Trials Group

NHL

Non-Hodgkin’s lymphoma

NPT

Non-protocol therapy

NR

Not reached

NSABP

National Surgical Adjuvant Breast and Bowel Project

NSAID

Nonsteroidal anti-inflammatory drug

NSCLC

Non-small cell lung cancer

NYHA

New York Heart Association

^Top

O

OHRP

Office of Human Research Protections

OR

Operating room

ORR

Objective response rate

OS

Overall survival

^Top

P

PCTA

Percutaneous transluminal angioplasty

PD

Progressive disease

PE

Pulmonary embolism

PFS

Progression-free survival

PR

Progesterone receptor

PS

Performance status

PT

Prothrombin time

PTT

Partial thromboplastin time

PVD

Peripheral vascular disease

PWB

Physical well-being

^Top

Q

QOL

Quality of life

^Top

R

RCI

Repeated confidence interval

RECIST

Response Evaluation Criteria in Solid Tumors

rhuMAb

Recombinant humanized monoclonal antibody

R/O’d

Ruled out

RTOG

Radiation Therapy Oncology Group

^Top

S

SAP

Statistical analysis plan

sBLA

Supplemental Biologics License Application

SBO

Small bowel obstruction

SD

Standard deviation

SE

Standard error

SGOT (AST)

Serum glutamic oxaloacetic transaminase

SGPT

Serum glutamic pyruvic transaminase

SIADH

Syndrome of inappropriate antidiuretic hormone secretion

SLD

Sum of longest diameter

SN38G

SN38 glucuronide

s/p

Status post

SWB

Social/family well-being

SWFI

Sterile Water for Injection

SWOG

Southwest Oncology Group

^Top

T

t1/2

Elimination half-life

TDQ

Time to deterioration in QOL

TOI

Trial Outcome Index

TOI-C

Trial Outcome Index—Colorectal

TP1

Treatment Period 1

TTP

Time to disease progression

^Top

U

UE

Unable to evaluate

UGT

UDP glucuronosyl-transferase

ULN

Upper limit of normal

USAN

United States adopted name

USP

United States Pharmacopeia

UTI

Urinary tract infection

^Top

V

V

Volume of distribution

VCAM

Vascular cell adhesion molecule

VCAM-1

Vascular cell adhesion molecule-1

VEGF

Vascular endothelial growth factor

VTE

Venous thromboembolic event

^Top

W

WBC

White blood cell count

WHO

World Health Organization

^Top

X

XRT

Radiotherapy

^Top